メインコンテンツに移動

Development Pipeline

EA Pharma Co., Ltd. Development Pipeline

as of October, 2021

Therapeutic
Area
Development Code
(Generic name)
Development Stage Indication Note
Gastrointestinal
diseases
Gastrointestinal
diseases
AJM300
(carotegrast methyl)
Submitted Ulcerative colitis α4 integrin antagonist
Oral
Gastrointestinal
diseases
E6007
(milategrast)
Phase II Ulcerative colitis Integrin activation inhibitor
Oral
Gastrointestinal
diseases
E6011
(quetmolimab)
Phase II Crohn's disease Anti-humanized monoclonal fractalkine antibody
Injection
Gastrointestinal
diseases
AJM347 Phase I Inflammatory bowel disease Oral
Gastrointestinal
diseases
EA1080 Phase I Inflammatory bowel disease Oral
Gastrointestinal
diseases
E3112 Phase I Liver disease Injection
Gastrointestinal
diseases
EA3355 Phase I Liver disease In-license (Dr. Falk Pharma)
Oral
Neurology Neurology EA4017 Phase I Chemotherapy-
induced peripheral neuropathy
Oral